CRD 512

Referencias correspondientes a la pieza CRD 512

1.Último prospecto aprobado por ANMAT.

2.McMurray JJV, Packer M, Desai AS, et al; for PARADIGM-HF Committees Investigators. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16(7):817-825.

3.Levin et al. N Engl J Med 1998;339:321–8; Nathisuwan & Talbert. Pharmacotherapy 2002;22:27–42.

4.Kemp & Conte. Cardiovascular Pathology 2012;365–371; Schrier & Abraham N Engl J Med 2009;341:577–85.

5.Langenickel & Dole. Drug Discov Today: Ther Strateg 2012;9:e131–9.

6.Antoniou T, et al. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular
disease in patients with diabetes: a population-based cohort study. CMAJ. 2013 Sep 3;185(12):1035-41.

7.Kurtz TW, Gardner DG (1998) Transcription-modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension 32:380-386

8.Organization WH: De nition, diagnosis and classi cation of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis adnclassi cation of diabetes mellitus. Edited by: WHO. World Health Organization; 1999:1-28.

9.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

10.Cruden NL, et al. Delay in lling rst clopidogrel prescription after coronary stenting is associated with an increased risk of death and myocardial
infarction. J Am Heart Assoc. 2014 May 28;3(3)

11.Ateinhubl S et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronaryintervention. A randamized controlled trial, JAMA 202 Nov 20: 288 (19):2411-20

12.Clinical impact of early clopidogrel discontinuation following acutemyocardial infarction hospitalization or stent implantation analysis in a nationally representative managed-care population. Wiederkehr D. BerensonK,Casciano R, Stern L, Makenbaeva D, Mazoffari e, Lamerato L, Cobelli J, Curr Med Res Opin, 2009 Sep: 25(9):2317-25

13.DiNicolantonio J., et al. “Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol)”. American Journal of Cardiology, Volume 111, Issue 5, Pages 765-
769, 1 March 2013.

14.Datos en archivo Laboratorios Bagó S.A.

15.Claudia Filozof, Sherwyn Schwartz, James E.Foley. Effect of vildagliptin as add-on therapy to a low-dose metformin. Word J Diabetes 2010 March 15;1(1);19-26

16.E. Bossi, F.Dotta, Y. Jia,and M.Goodman. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual
monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 11,2009,506-515

 

ADVERTENCIA:

El material incluido en este sitio ha sido concebido exclusivamente para los profesionales de la salud con fines informativos, y destinado a orientar sobre el uso adecuado de los medicamentos y a satisfacer sus necesidades de mayor información.

Todos los textos referidos a nuestros productos de venta bajo prescripción médica se corresponden a los lineamientos aprobados por la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).

Laboratorios Bagó le sugiere consultar siempre a un profesional de la salud calificado ante cualquier duda sobre una condición médica particular.

He comprendido y deseo ver la información

Consultas médicas: infoproducto@bago.com.ar